Background Analysis: US FDA Advisory Committee to Review Eli Lilly’s Necitumumab for Squamous Non-small Cell Lung Cancer – JUL 9, 2015 (ODAC)
The U.S. FDA has scheduled an Oncologic Drugs Advisory Committee (ODAC) meeting for Thursday, July 9, 2015. The Committee will discuss biologics license application 125547, necitumumab injection, submitted by Eli Lilly and Company. The proposed indication for this product is in combination with gemcitabine and cisplatin for first-line treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer.